Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Administrative Data
Compared with people without cancer, patients with NETs had a higher prevalence of comorbidities and concomitant medication use, which was associated with a greater economic burden.
Authors
- Antônio Ribeiro‐Oliveira (ORCID: https://orcid.org/0000-0002-6114-5786)
- Aude Houchard (ORCID: https://orcid.org/0000-0001-6248-8986)
- Syvart Dennen (ORCID: https://orcid.org/0000-0001-9872-4004)
- Jason S. Starr (ORCID: https://orcid.org/0000-0003-4922-1392)
- Timon Vandamme (ORCID: https://orcid.org/0000-0003-3701-5305)
- Yajin Zhao (ORCID: https://orcid.org/0000-0002-3751-3892)
- Christelle Pommie (ORCID: https://orcid.org/0009-0001-8771-2304)
- Yutong Liu (ORCID: https://orcid.org/0009-0009-3844-9456)
- Sai Sriteja Boppudi Naga
- Jennifer Ang Chan (ORCID: https://orcid.org/0000-0003-2523-9598)
Institutions
- University of Antwerp (BE)
- Ipsen (France) (FR)
- Antwerp University Hospital (BE)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Ipsen (United States) (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1007/s12325-025-03126-6
- Citations
- 3
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Ipsen